Protagenic Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.5M
- Price
- $0.8011
- % Change (Daily % change from the live per-ticker quote feed.)
- +33.52%
- Volume
- 140.6K
About
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
Quick stats
Shares outstanding1.8M
Computed float1.2M
Float / shares69.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001022899
Websitehttps://phytanix.com
AI Summary
AI-generated1/4
standardbullishregulatory
Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
Protagenic received written feedback from the FDA regarding its pre-IND meeting request for PT00114, with the agency raising no objections to the planned Phase 1 program design or CMC strategy.
Management confirmed that the IND submission remains on track for the fourth quarter of 2026, with first patient dosing targeted for the first half of 2027.
The favorable response allows the company to carry forward prior ex-U.S. clinical data into its U.S. development program for generalized anxiety disorder.
Red flags
- Company discloses 'substantial doubt about its ability to continue as a going concern'
- Forward-looking statements highlight need for substantial additional capital